Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Luca Pani

Showing results (101-110 of 140) with videos related to

Pageof 14
Sort By:
Journal of Psychopharmacology (Oxford, England)|July 16, 2019
Microdosing psychedelics: More questions than answers? An overview and suggestions for future researchKim Pc Kuypers, Livia Ng, David Erritzoe, et al.
Psychiatric Services (Washington, D.C.)|September 4, 2004
Practical application of pharmacotherapy with long-acting risperidone for patients with schizophreniaSamuel J Keith, Luca Pani, Beat Nick, et al.
European Journal of Pharmacology|December 31, 2002
Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tractMaria Antonietta Casu, Anna Porcella, Stefania Ruiu, et al.
Bioorganic & Medicinal Chemistry|April 6, 2005
Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptorsGabriele Murineddu, Stefania Ruiu, Jean-Mario Mussinu, et al.
Psychopathology|January 14, 2011
Unexplained somatic symptoms during major depression: prevalence and clinical impact in a national sample of Italian psychiatric outpatientsGiulio Perugi, Pier Luigi Canonico, Paolo Carbonato, et al.
The Open Medicinal Chemistry Journal|August 10, 2012
Tricyclic Pyrazoles. Part 5. Novel 1,4-Dihydroindeno[1,2-c]pyrazole CB2 Ligands Using Molecular Hybridization Based on Scaffold HoppingGabriele Murineddu, Battistina Asproni, Stefania Ruiu, et al.
British Journal of Clinical Pharmacology|November 23, 2017
Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plansLeroy R A Lepelaars, Francesca Renda, Luca Pani, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 1, 2016
Scaling up health knowledge at European level requires sharing integrated data: an approach for collection of database specificationEnrica Menditto, Angela Bolufer De Gea, Caitriona Cahir, et al.
Neuropsychiatric Disease and Treatment|May 17, 2011
Prevalence and diagnostic distribution of medically unexplained painful somatic symptoms across 571 major depressed outpatientsMichele Fornaro, Icro Maremmani, Pier Luigi Canonico, et al.
Journal of Medicinal Chemistry|December 8, 2006
Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamideGabriele Murineddu, Paolo Lazzari, Stefania Ruiu, et al.
Pageof 14

Showing results (101-110 of 140) with videos related to

Sort By:
Pageof 14
Journal of Psychopharmacology (Oxford, England)|July 16, 2019
Microdosing psychedelics: More questions than answers? An overview and suggestions for future researchKim Pc Kuypers, Livia Ng, David Erritzoe, et al.
Psychiatric Services (Washington, D.C.)|September 4, 2004
Practical application of pharmacotherapy with long-acting risperidone for patients with schizophreniaSamuel J Keith, Luca Pani, Beat Nick, et al.
European Journal of Pharmacology|December 31, 2002
Differential distribution of functional cannabinoid CB1 receptors in the mouse gastroenteric tractMaria Antonietta Casu, Anna Porcella, Stefania Ruiu, et al.
Bioorganic & Medicinal Chemistry|April 6, 2005
Tricyclic pyrazoles. Part 2: Synthesis and biological evaluation of novel 4,5-dihydro-1H-benzo[g]indazole-based ligands for cannabinoid receptorsGabriele Murineddu, Stefania Ruiu, Jean-Mario Mussinu, et al.
Psychopathology|January 14, 2011
Unexplained somatic symptoms during major depression: prevalence and clinical impact in a national sample of Italian psychiatric outpatientsGiulio Perugi, Pier Luigi Canonico, Paolo Carbonato, et al.
The Open Medicinal Chemistry Journal|August 10, 2012
Tricyclic Pyrazoles. Part 5. Novel 1,4-Dihydroindeno[1,2-c]pyrazole CB2 Ligands Using Molecular Hybridization Based on Scaffold HoppingGabriele Murineddu, Battistina Asproni, Stefania Ruiu, et al.
British Journal of Clinical Pharmacology|November 23, 2017
Comparing safety information of biosimilars with their originators: a cross-sectional analysis of European risk management plansLeroy R A Lepelaars, Francesca Renda, Luca Pani, et al.
Clinicoeconomics and Outcomes Research : CEOR|July 1, 2016
Scaling up health knowledge at European level requires sharing integrated data: an approach for collection of database specificationEnrica Menditto, Angela Bolufer De Gea, Caitriona Cahir, et al.
Neuropsychiatric Disease and Treatment|May 17, 2011
Prevalence and diagnostic distribution of medically unexplained painful somatic symptoms across 571 major depressed outpatientsMichele Fornaro, Icro Maremmani, Pier Luigi Canonico, et al.
Journal of Medicinal Chemistry|December 8, 2006
Tricyclic pyrazoles. 4. Synthesis and biological evaluation of analogues of the robust and selective CB2 cannabinoid ligand 1-(2',4'-dichlorophenyl)-6-methyl-N-piperidin-1-yl-1,4-dihydroindeno[1,2-c]pyrazole-3-carboxamideGabriele Murineddu, Paolo Lazzari, Stefania Ruiu, et al.
Pageof 14